A Phase I Dose Escalation and Pharmacodynamic Study of SU5416 (Semaxanib) Combined with Weekly Cisplatin and Irinotecan in Patients with Advanced Solid Tumors
A Phase I Dose Escalation and Pharmacodynamic Study of SU5416 (Semaxanib) Combined with Weekly Cisplatin and Irinotecan in Patients with Advanced Solid Tumors
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started